Rexahn Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results
March 14, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., March 14, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment...
Rexahn Announces $5 Million Registered Direct Offering
February 26, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into a definitive agreement with a single healthcare dedicated...
Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma
February 08, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of...
Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016
February 01, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of...
Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations at the 2016 Gastrointestinal Cancers Symposium
January 25, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition
January 12, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
Rexahn Pharmaceuticals’ Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study
January 11, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2016
January 05, 2016 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
Rexahn Pharmaceuticals Announces New Data for Supinoxin™ Showing Potent Tumor Growth Inhibition
December 14, 2015 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
Rexahn Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference on November 18, 2015
November 11, 2015 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, MD, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...